TrialDiabetes care2012

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).

Vivian A Fonseca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.